MILFORD, Pa., Sept. 29, 2014 /PRNewswire/ -- Manzo
Pharmaceuticals, Inc. (OTCPink:FOGCD), today announced at the three
month mark in a six month animal study, that the results of the
lactase producing probiotic, Lacto-Freedom™, has been very
successful. This successful testing brings Manzo
Pharmaceuticals, and partner, Celprogen, Inc., one step closer to
human clinical trials.
The 6-month study is being conducted by Celprogen,Inc. using
laboratory rats to test the new probiotic treatment. Lab rats are
the ideal mammals to test because they are naturally lactose
intolerant. After 3 months the rats given the treatment showed no
negative side effects, even at very high doses. All doses
from low to high concentration were very successful at colonizing
the intestines and producing lactase, which enabled rats to digest
lactose. This effect lasted for a full three months after the
administration of the probiotic was
discontinued. This long lasting residual effect
is unique and is far superior to any other lactose
intolerance treatment option currently on the market. Since
approximately 25% of the population in the United States is lactose intolerant Manzo
Pharmaceuticals and Celprogen are both confident that there
will be a huge demand for this product.
Jay Sharma, CEO of Celprogen,
stated, "we are very pleased with the results so far and everyone
is eager to see how long the effects last. Its possible that the
effects could last six months or beyond, and because of that we
would like to start looking for a company to do a small human
clinical trial"
In addition to the tremendous progress with Lacto-Freedom™,
Manzo Pharmaceutical CEO, Ken Manzo
wants shareholders to know that although he has been occupied with
the recent name change and corporate re-structuring he has been
keeping shareholder value in mind, and recently filed for a
reduction in authorized shares from 5 Billion to only 950 million
because he wants to control and limit future dilution, therefore
maintaining and growing shareholder value. It's clear that Manzo
Pharmaceuticals is positioning itself to be a powerful player in
the pharmaceutical industry.
DISCLAIMER
This Press Release may contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. The Company has tried, whenever possible, to
identify these forward-looking statements using words such as
"anticipates," "believes," "estimates," "expects," "plans,"
"intends," "potential" and similar expressions. These statements
reflect the Company's current beliefs and are based upon
information currently available to it. Accordingly, such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance or achievements to differ materially
from those expressed in or implied by such statements. The Company
undertakes no obligation to update or advise in the event of any
change, addition or alteration to the information catered in this
Press Release including such forward-looking statements.
SOURCE Manzo Pharmaceuticals, Inc.